Equivocal results from its first pivotal Phase III trial with OMS103HP in knee surgery shaved Omeros Corp.'s stock, but gave the company a roadmap for the next study, which will use postoperative pain – a secondary endpoint, met in the latest experiment – as the primary outcome goal.